酪酸梭菌二联活菌散联合头孢唑肟钠治疗抗生素相关性腹泻患儿的效果

Effects of combined Clostridium Butyricum and Bifidobacterium powders,live combined with Ceftizoxime sodium in treatment of children with antibiotic-associated diarrhea

目的:观察酪酸梭菌二联活菌散联合头孢唑肟钠治疗抗生素相关性腹泻(AAD)患儿的效果。方法:选取2022年3月至2023年5月该院收治的74例AAD患儿进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各37例。两组均予以常规治疗,在此基础上,对照组予以头孢唑肟钠治疗,研究组在对照组基础上联合酪酸梭菌二联活菌散治疗,两组均治疗3 d。比较两组临床疗效,临床相关指标(止泻时间、大便性状恢复正常时间和住院时间)水平,治疗前后肠道菌群(双歧杆菌、乳杆菌、大肠埃希菌、真杆菌)数量、炎性因子[C反应蛋白(CRP)、白细胞介素(IL)-2、IL-6、肿瘤坏死因子-α(TNF-α)、降钙素原(PCT)]水平,以及不良反应发生率。结果:研究组治疗总有效率为97.30%(36/37),高于对照组的78.38%(29/37),差异有统计学意义(P<0.05);研究组止泻时间、大便性状恢复正常时间、住院时间均短于对照组,差异有统计学意义(P<0.05);治疗后,研究组乳杆菌、双歧杆菌、真杆菌数量多于对照组,大肠埃希菌数量少于对照组,差异均有统计学意义(P<0.05);治疗后,研究组TNF-α、CRP、IL-6、PCT、IL-2水平均低于对照组,差异有统计学意义(P<0.05);两组治疗期间均未出现明显不良反应。结论:酪酸梭菌二联活菌散联合头孢唑肟钠治疗AAD患儿可提高治疗总有效率,改善临床指标水平,调节肠道菌群数量,降低炎性因子水平,效果优于单纯头孢唑肟钠治疗。

Objective:To observe effects of combined Clostridium Butyricum and Bifidobacterium powders,live combined with Ceftizoxime sodium in treatment of children with antibiotic-associated diarrhea(AAD).Methods:A prospective study was conducted on 74 children with AAD admitted to this hospital from March 2022 to May 2023.According to the random number table method,they were divided into control group and study group,37 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Ceftizoxime sodium,while the study group was treated with combined Clostridium Butyricum and Bifidobacterium powders,live on the basis of that of the control group.Both groups were treated for 3 d.The clinical efficacy,the levels of clinical related indicators(antidiarrheal time,stool character recovery time and hospitalization time),the number of intestinal flora(Bifidobacterium,Lactobacillus,Escherichia coli,Eubacterium)and the levels of inflammatory factors[C-reactive protein(CRP),interleukin(IL)-2,IL-6,tumor necrosis factor-α(TNF-α),procalcitonin(PCT)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 97.30%(36/37),which was higher than 78.38%(29/37)of the control group,and the difference was statistically significant(P<0.05).The antidiarrheal time,the stool character recovery time and the hospitalization time in the study group were shorter than those in the control group,the differences were statistically significant(P<0.05).After the treatment,the number of Lactobacillus,Bifidobacterium and Eubacterium in the study group was more than that in the control group,the number of Escherichia coli was less than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of TNF-α,CRP,IL-6,PCT and IL-2 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there were no obvious adverse reactions in the two groups during the treatment.Conclusions:Combined Clostridium Butyricum and Bifidobacterium powders,live combined with Ceftizoxime sodium in the treatment of the children with AAD can improve the total effective rate of treatment,improve the levels of clinical indicators,regulate the number of intestinal flora,and reduce the levels of inflammatory factors.Moreover,it is superior to simple Ceftizoxime sodium treatment.